Neurocrine Biosciences未能达到盈利预期，但收入增长，内部人士则抛售了股票。 Neurocrine Biosciences missed earnings estimates but saw revenue growth, while insiders sold shares.

神经生物科学公司报告说,第二季度收入为1.88 EPS,略低于估计数,收入8.055亿美元,比上一年增加28.3%。 Neurocrine Biosciences reported second-quarter earnings of $1.88 EPS, slightly below estimates, with $805.5 million in revenue, up 28.3% year-over-year. 股票以129.78美元关闭,市场上限为130.2亿美元,并获得协商一致的“货币买入”评级。 The stock closed at $129.78, with a market cap of $13.02 billion and a consensus "Moderate Buy" rating. 布恩资本管理公司减少了13,924股持股，内部人士在三个月内出售了42,590股，市值578万美元。 Boone Capital Management reduced its stake by 13,924 shares, and insiders sold 42,590 shares valued at $5.78 million in three months. 分析家预测该年度的EPS为4.28美元,该公司的主要药物Ingrezza治疗迟滞性躁郁症。 Analysts forecast $4.28 EPS for the year, and the company’s lead drug, Ingrezza, treats tardive dyskinesia.